{"disease":{"id":"primary-hyperoxaluria-type-1-ph1","name":"primary hyperoxaluria type 1 ph1"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04042402","title":"Long Term Extension Study in Patients With Primary Hyperoxaluria","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":75,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":false},{"nct_id":"NCT02706886","title":"Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT03681184","title":"A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT03847909","title":"A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT03905694","title":"A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT05993416","title":"Treatment of Primary Hyperoxaluria Type 1 With Nedosiran","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}